jCyte Inc


jCyte, Inc. is a clinical-stage biotech company focused on developing its first-in-class allogeneic cell therapy, jCell, for retinitis pigmentosa (RP) and other retinal degenerative disorders. The treatment has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation and is administered as a minimally invasive intravitreal injection. Currently there are no FDA approved therapies for over 99% of RP patients. The company is pioneering a new era of regenerative therapies to address the significant unmet medical needs of patients suffering from a broad set of retinal degenerative diseases.


Get Involved At World Orphan Drug Congress USA


To Sponsor Or Exhibit


Justin Franks
t/ +1 914 819 3506




To Speak


Gina McHugh
t/ +1 646 619 1775




Marketing & Press Opportunities


Kaylie Brogan